The new form of proton therapy is called FLASH and is designed to deliver cancer-killing radiation therapy in less than a second.
An effort is underway to identify biological changes that signal whether people carrying a genetic variant will develop ALS or frontotemporal dementia.
The Smilow Foundation’s gift will advance gene editing and other precision therapies for cardiovascular disease.
Penn researchers earned NIH Director’s Awards supporting innovative studies of disease, housing design, and human health.
After more than a decade at Penn Medicine, cancer researcher Ronny Drapkin, MD, PhD, will join Wistar as President & CEO in November 2026.
Financial incentives of up to $600 nearly doubled verified quit rates among medically underserved adults undergoing lung cancer screening.
Senior HealthLink, a program pairing seniors with nursing students for regular check-ins, shows that sometimes just showing up is the best medicine.
A newly uncovered genetic variant can leave central vision relatively untouched but causes loss of peripheral and low-light vision.
Many rotator cuff repairs fail due to a variety of factors that could be solved by a new fix that imitates the body’s natural environment.
Clinicians may soon have a clearer picture of how babies are tolerating labor through a new federally funded effort to develop a wearable monitor.
Scientists discovered a mechanism that allows cells to develop an “immune memory” and keep themselves in a heightened antiviral state to respond more strongly to viral infection. — Sept. 3, 2026
Mutations in the NRXN1 gene have been linked to autism and other disorders, yet studying these mutations is tricky. But a team revealed unprecedented detail in the gene’s mutations using a new zebrafish model. — July 23, 2026
Within a group of long-term responders who’d received CAR T treatment, researchers found patients usually still had evidence of the cells in their blood after five years, including one patient with detectable cells after ten years. — Aug. 10, 2026
The customizable, human-in-the-loop AI framework uses public data to find viable target antigens for CAR T cell therapy.
Many patients with large B-cell lymphoma or follicular lymphoma were still living without a relapse, 10 years after receiving CAR T therapy.
An early trial demonstrates CAR T cells can safely desensitize even the most challenging transplant candidates.
Bilateral hand transplant at Penn Medicine gives Swiss man new hands 16 years after childhood amputations.
A national review finds uterus transplants have led to dozens of healthy births as surgical outcomes continue to improve.
By finding retinal cell subgroups in mice, researchers hope to pinpoint an optimal cell type for transplants to restore vision in blinding conditions.
A Penn-developed nanoparticle platform could make mRNA vaccines easier to produce, store, and distribute.
Every minute in the U.S., a woman needs a blood transfusion due to her period. Kathleen O’Neill, MD, is working to develop a novel therapy to protect women.
A new DNA delivery method could transform treatment for millions suffering from common chronic diseases like heart disease, diabetes, and cancer.
The science of cancer interception is advancing at Penn Medicine with a new platform to develop cancer vaccines piling scientific strength upon strength.
Through the Basser Center for BRCA Postdoctoral Fellowship Program, the Sands are cultivating the next generation of discovery to intercept cancer.
The Basser Center for BRCA is running an innovative cancer interception clinical trial that depends on volunteers with deep, personal ties to cancer.
With a focus on strategy and research, Katie Dalke, MD, MBE, and Dovie Watson, MD, MSCE, build on Penn Medicine’s commitment to inclusive care.
Using organoids as models of human brains and brain cancer, Hongjun Song, PhD, and Guo-li Ming, MD, PhD, are making major scientific advances together.
A decentralized approach modeled on the immune system detected more disease-carrying insects than conventional surveillance in Peru.
Public investments in biomedical research have an outsized effect, driving new scientific insights, economic growth, and ultimately treatments and cures.
The successes of CAR T research show the importance of the cycle of science—sparking new ideas and clinical trials that give patients better options.
The Penn Medicine Co-Investment program spurs faculty innovation, creates jobs, and helps scale up ideas into large-scale clinical studies.
